Internal Reference Number: FOI_6825
Date Request Received: 13/10/2022 00:00:00
Date Request Replied To: 20/10/2022 00:00:00
This response was sent via: By Email
Request Summary: Lung cancer
Request Category: Researcher
| Question Number 1: In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with: • Afatinib • Alectinib • Amivantamab • Atezolizumab monotherapy • Atezolizumab with chemotherapy • Brigatinib • Ceritinib • Crizotinib • Dacomitinib • Dabrafenib with Trametinib • Durvalumab • Erlotinib • Gefitinib • Lorlatinib • Mobocertinib • Nintedanib with Docetaxel • Nivolumab • Osimertinib • Pembrolizumab monotherapy • Pembrolizumab with chemotherapy • Pemetrexed with Carboplatin/Cisplatin • Pralsetinib • Selpercatinib • Sotorasib • Tepotinib • Vinorelbine with Carboplatin/Cisplatin • Any other active systemic anti-cancer therapy (SACT) • Palliative care only | |
| Answer To Question 1: Q. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with: • Afatinib 0 • Alectinib <5 • Amivantamab 0 • Atezolizumab monotherapy 0 • Atezolizumab with chemotherapy <5 • Brigatinib 0 • Ceritinib 0 • Crizotinib <5 • Dacomitinib 0 • Dabrafenib with Trametinib <5 • Durvalumab <5 • Erlotinib 0 • Gefitinib <5 • Lorlatinib <5 • Mobocertinib 0 • Nintedanib with Docetaxel 0 • Nivolumab 0 • Osimertinib 10 • Pembrolizumab monotherapy 11 • Pembrolizumab with chemotherapy <5 • Pemetrexed with Carboplatin/Cisplatin <5 • Pralsetinib 0 • Selpercatinib 0 • Sotorasib <5 • Tepotinib 0 • Vinorelbine with Carboplatin/Cisplatin <5 • Any other active systemic anti-cancer therapy (SACT) none listed • Palliative care only - We do not hold this information. | |
| Question Number 2: In the past 3 months, how many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY with the following drugs: • Atezolizumab monotherapy • Atezolizumab with chemotherapy • Durvalumab • Nivolumab • Osimertinib • Pembrolizumab (Keytruda) Mono • Pembrolizumab (Keytruda) with Chemotherapy • Tepotinib • Other active systemic anti-cancer therapy (SACT) • Palliative care only | |
| Answer To Question 2: • Atezolizumab monotherapy 0 • Atezolizumab with chemotherapy 0 • Durvalumab <5 • Nivolumab 0 • Osimertinib 0 • Pembrolizumab (Keytruda) Mono <5 • Pembrolizumab (Keytruda) with Chemotherapy 0 • Tepotinib 0 • Other active systemic anti-cancer therapy (SACT) <5 • Palliative care only We do not hold this information | |
| Question Number 3: Do you participate in any clinical trials for non-small cell lung cancer (NSCLC)? If so, could you please provide the name of each trial and the number of patients taking part. | |
| Answer To Question 3: SFT does not currently have any clinical trials for NSCLC open to recruitment, in follow up or in set-up. We opened to QUARTZ in 2007 but did not recruit any participants. | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
